Background The relationships between uric acid and metabolic syndrome (MetS) 
Introduction

Uric acid is the final oxidation product of purine catabolism and increased serum concentrations of uric acid have been implicated in cardiovascular disease. Facchini et al demonstrated that urinary uric acid clearance decreases in proportion to the increase in insulin resistance leading to an increase in serum uric acid concentration (1). Thus, uric acid may be a component of insulin resistance syndrome or metabolic syndrome (MetS) (2-5). Various mechanisms have been suggested through which uric acid may be implicated in the atherosclerotic process and its clinical complications. However, the contribution of uric acid to atherosclerotic vascular disease is still controversial. Uric acid can act as a prooxidant, particularly at increased concentrations, and may thus be a marker of oxidative stress, but it may also have a therapeutic role as an antioxidant (6). Patterson et al, using a normal human serum ultrafiltrate, demonstrated that uric acid protects native low-density lipoprotein (LDL) against oxidation by transition metal ions, but it accelerates the oxidation of mildly oxidized LDL (7). Thus, although there are plausible mechanisms to suggest uric acid as a potential direct mediator of MetS, diabetes, and cardiovascular disease, the relationships between uric acid and diabetes and cardiovascular disease are controversial and there may be gender and ethnic differences in these relationships
.
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Discussion
The concept of insulin resistance syndrome (syndrome X) (2) or MetS (3, 4) (20) (21) (22) (23) (18, 19) T a b l e 3 . S p e a r ma n ' s Co r r e l a t i o n Co e f f i c i e n t s b e t T a b l e 5 . S p e a r ma n ' s Co r r e l a t i o n Co e f f i c i e n t s b e t (14) . The correlation between serum uric acid and fasting glucose was negative in Austrian men (10) and was not significant in Japanese men in the present study. Serum uric acid has been described as being increased in the prediabetic stage of diabetes and as being decreased in overt diabetes (29) . Conflicting data exist about uric acid levels in type 2 diabetes, as low levels were found in overt diabetes, while elevated serum uric acid is a feature of insulin resistance and impaired glucose tolerance (30) . Bo 
. Criteria that regard obesity as an inevitable component of MetS have a serious pit hole because there are a substantial number of metabolically obese normal weight individuals (24) and only about one-third of most insulin-resistant individuals are actually obese (22). An essential drawback of JMetS (visceral fat syndrome) (15) is that it regards subcutaneous adipose tissue as a protective factor against the morbid effect of visceral adipose tissue and ignores the risk contribution of abdominal subcutaneous adipose tissue (25-27). A detailed criticism was discussed in a recent review by Oda (28). JMetS or IDF MetS where obesity is an inevitable component is already revealed to be inferior to the revised NCEP MetS as a predictor of cardiovascular disease in Japanese
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